Benefits of Combination Therapy with Flutamide in Patients Relapsing after Castration
- 1 April 1988
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 61 (4) , 341-346
- https://doi.org/10.1111/j.1464-410x.1988.tb13971.x
Abstract
Summary— Two hundred and nine patients with biopsy‐proven stage D2 prostatic carcinoma showing disease progression after orchiectomy or treatment with DES (stilboestrol) or an LHRH agonist alone received combination therapy with the pure antiandrogen flutamide. In patients treated with DES, the oestrogen was replaced by the LHRH agonist [D‐Trp6]LHRH ethylamide. The objective response to therapy was assessed according to the criteria of the US NPCP. Thirteen patients had a complete response to treatment, while partial and stable responses were achieved in 20 and 39 patients respectively (total objective response rate of 34.5%). The mean duration of response was 24 months. In the non‐responders the median survival was 8.1 months with a 17% probability of survival at 2 years; the probabilities of survival at 2 years of the patients who showed partial and stable responses were 87 and 67% respectively. All patients who achieved a complete response are still alive. Combination therapy with Flutamide and castration (surgical or LHRH agonist) appears to be the treatment of choice for prostate cancer patients in relapse after standard endocrine therapy.This publication has 33 references indexed in Scilit:
- A wide range of sensitivities to androgens develops in cloned shionogi mouse mammary tumor cellsThe Prostate, 1986
- LOSS OF LUTEINIZING HORMONE BIOACTIVITY IN PATIENTS WITH PROSTATIC CANCER TREATED WITH AN LHRH AGONIST AND A PURE ANTIANDROGENClinical Endocrinology, 1986
- Flutamide Therapy for Advanced Prostatic Cancer: a Phase II StudyBritish Journal of Urology, 1985
- Treatment of advanced prostatic cancer, resistant to conventional therapy with aminoglutethimideEuropean Journal of Cancer and Clinical Oncology, 1985
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983
- Androgen of the Human ProstateEndocrine Research Communications, 1976
- Adrenal Suppression in the Treatment of Carcinoma of the ProstateBritish Journal of Urology, 1974
- Therapy with orchiectomy or estrogens or bothPublished by American Medical Association (AMA) ,1969
- A CLINICAL EVALUATION OF RADIOACTIVE PITUITARY IMPLANTATION IN THE TREATMENT OF ADVANCED CARCINOMA OF THE PROSTATE1British Journal of Urology, 1962